When no validated method exists, we build one.

Method development is not a 'nice-to-have'. It is the foundation upon which everything else depends.

Not every product can be found in the pharmacopoeia.

New compounds, complex matrices, unusual formulations, innovative food ingredients—for many of the products our clients develop or manufacture, a validated analytical method simply does not exist yet. Without such a method, there is no reliable way to measure quality, confirm identity, quantify impurities, or comply with laws and regulations.

Method development is therefore relevant within every sector we serve.

Method development is not a matter of trial and error.

Building a reliable analytical method requires systematic scientific thinking, a deep understanding of the matrix, and the ability to foresee how the method will perform under real-world conditions, not just on a good day in the laboratory.

01

/

Matrix complexity

The product matrix determines everything. A method that works for a pure compound will fail in a complex formulation. We design for the actual matrix from day one, not for an idealized version of it.

02

/

Regulatory expectations

A method that cannot be validated is a method that cannot be used. We build from the start with ICH Q2(R1) validation in mind: specificity, linearity, accuracy, precision, range, and robustness.

03

/

Transfer & reproducibility

A method must work not only in our hands, but also when transferred to another laboratory or used for routine analysis over many years. We design for reproducibility, not just for a one-off result.

Expertise

Reliability

Flexibility

Partnership

From analytical challenge to validated method.

Every method development project at Brightlabs follows a structured workflow, from understanding the analytical challenge to delivering a fully validated, transferable method.

01

/

Defining the analytical goal

What exactly do you need to measure, in which matrix, at what concentration, and with what level of certainty? We start by precisely defining the question, because a vague question leads to a vague method.

02

/

Selecting and optimizing the technique

Based on the target compound, the matrix, and the required sensitivity, we select the most appropriate technique (HPLC, GC, LC-MS, ICP-MS) and optimize the conditions: column, mobile phase, gradient, and detection parameters.

03

/

Developing and stress-testing the method

We test the method against extreme scenarios, including matrix interference, degraded samples, and extreme concentrations, to ensure it performs reliably under conditions that go beyond the ideal.

04

/

Validation according to ICH standards

Full validation in accordance with ICH Q2(R1): specificity, linearity, accuracy, precision, range, limits of detection and quantification, and robustness. Fully documented and audit-ready.

05

/

Documentation and transfer

We provide a complete method package: the validated protocol, documentation, SOPs, and, where necessary, support for transferring the method to your own QC laboratory or a third party.

Sectoren waar methodeontwikkeling essentieel is.

Farma

Nieuwe verbindingen, complexe formuleringen, generieke geneesmiddelen

Cannabis

Plantaardige matrices, innovatieve CBD-producten, niet-standaard extracten

Voeding

Innovatieve ingrediënten, bijproducten, niet-standaard matrices

Industry

Klantspecifieke verbindingen en industriële materialenerialen

Verder verkennen.

Nitrosamine analysis

Brightlabs develops advanced analytical methods for the detection of nitrosamines and API-specific nitrosamine impurities (NDSRIs), enabling pharmaceutical organizations to comply with stringent regulations.

Impurity Analysis

Impurities often determine the difference between an approved and a rejected product. We bring them into focus.

Stability studies

Stability studies answer a question required by every regulatory dossier: how does your product behave over time?

Insights from our laboratory

Innovation for Health

Jeroen Wijker and Figo Seelen are on site speaking with companies that are pushing new therapies, technologies, and products forward.

Brightlabs appoints COO

Today, we are pleased to announce the strengthening of our team with the appointment of Dr. Sander Kok as Chief Operating Officer.

Put the soil to work for resilient crops

Brightlabs and Soil Vision have jointly developed a smart analysis method that reveals how soil life functions and how you can optimize it.

The complete overview of what Brightlabs does.

Download our brochure for a complete overview of our analytical capabilities, services, and scientific approach.